The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895

CADTH read with interest the commentary published on 16 December 2022, entitled "Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain" [...].

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current oncology (Toronto) 2023-05, Vol.30 (5), p.5047-5049
Hauptverfasser:	Trudeau, Maureen, Fraser, Brent
Format:	Artikel
Sprache:	eng
Schlagworte:	Advisory Committees Breast Neoplasms - drug therapy Canada Comment Female Humans n/a Neoadjuvant Therapy Receptor, ErbB-2 Trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	CADTH read with interest the commentary published on 16 December 2022, entitled "Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain" [...].
ISSN:	1718-7729 1198-0052 1718-7729
DOI:	10.3390/curroncol30050380